ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Gemcitabine

Also written as “gemcitabine”, “gemcitabine hydrochloride” and “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”.

Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Biliary Tract Neoplasms, led by 30 companies.

Drug pageGemcitabine: every studyMany companies study it; this page follows only the 128 they lead. All 1,376 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 6, 2000128 company-led studies, 9 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly681 open or runningphase 3since Nov 6, 2000Nov 6, 2000May 2027phase 2 · NCT05999994
Hoffmann-La Rocheits history only181 open or runningphase 4since Mar 19, 2008Apr 17, 2007Mar 22, 2027phase 1 · NCT06624085
Pfizerits history only50 open or runningphase 3since Jan 21, 2000Jan 21, 2000none ahead
GlaxoSmithKlineits history only40 open or runningphase 2since May 23, 2003May 23, 2003none ahead
Amgenits history only30 open or runningphase 2since Jul 5, 2000Jul 5, 2000none ahead
Astellas Pharmaits history only20 open or runningphase 1since Apr 9, 2002Apr 9, 2002none ahead
NovoCureits history only20 open or runningphase 2since Oct 23, 2013Oct 23, 2013none ahead
Pierre Fabreits history only20 open or runningphase 2since Apr 16, 2012Apr 16, 2012none ahead
Sarah Cannon Research Instituteits history only20 open or runningphase 2since Apr 4, 2008Apr 4, 2008none ahead
Theriva Biologics SLits history only20 open or runningphase 1since Jan 21, 2014Jan 21, 2014none ahead

Also a collaborator on its studies: Ono Pharmaceutical, Baili-Bio (Chengdu) Pharmaceutical, AbbVie, Bristol-Myers Squibb, Criterium, AstraZeneca, PharmaBio Development, Johnson & Johnson, PPD DEVELOPMENT, LP, Merck, Sanofi and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since May 28, 2003.

  1. Sep 12, 200525 phase 2 studiesNCT00192101, NCT00192075, NCT00192062 and 22 more
  2. Sep 12, 20057 phase 3 studiesNCT00191646, NCT00191477, NCT00191438 and 4 more
  3. Apr 18, 20062 phase 2 studies in Breast NeoplasmsNCT00316199, NCT00320541
  4. May 15, 2006Phase 2 study in Pancreatic NeoplasmsNCT00326911 · 61 enrolled · United States
  5. Jun 6, 2006Phase 2 study in Breast NeoplasmsNCT00334802 · 62 enrolled · Japan
  6. Jul 24, 2006Phase 2 study in Lung NeoplasmsNCT00356525 · 41 enrolled · United States, Brazil, India
  7. Sep 22, 20062 phase 2 studiesNCT00380588, NCT00383331
  8. Jun 20, 20078 phase 2 studiesNCT00490399, NCT00489996, NCT00489983 and 5 more
  9. Feb 13, 2008Phase 2 study in Breast NeoplasmsNCT00623233 · 52 enrolled · United States
  10. Jul 8, 2010Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01160744 · 280 enrolled · United States, Belgium, Canada and more
  11. May 24, 2012Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01606748 · 35 enrolled · United States
  12. Oct 20, 2016Phase 2 study in Thoracic NeoplasmsNCT02941601 · United States, Belgium, Germany and more
  13. Dec 1, 2016Phase 2 study in Pancreatic NeoplasmsNCT02981342 · 106 enrolled · United States, Australia, Belgium and more
  14. Aug 14, 2023Phase 2 study in NeoplasmsNCT05999994 · 105 planned · United States, Australia, Belgium and more

Ahead

  1. May 2027Primary completion: phase 2 study in NeoplasmsNCT05999994

TargetBeta

“Ribonucleoside-diphosphate reductase RR1 inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
HydroxyurearuleNorginephase 415

Studies

The newest 60 of 68 Eli Lilly leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT05999994Neoplasms · United States, Australia, Belgium and more2RecruitingMay 2027105
NCT02981342Pancreatic Neoplasms · United States, Australia, Belgium and more2CompletedApr 20, 2018106
NCT02941601Thoracic Neoplasms · United States, Belgium, Germany and more2WithdrawnDec 20170
NCT01606748Carcinoma, Non-Small-Cell Lung · United States2CompletedJun 201335
NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2CompletedJan 2014280
NCT00623233Breast Neoplasms · United States2CompletedJan 201152
NCT00491127Lymphoma, Non-Hodgkin · Spain2Completed10
NCT00491114Urinary Bladder Neoplasms · Italy2Completed8
NCT00490880Urinary Bladder Neoplasms · Poland2Completed2
NCT00490711Carcinoma, Ovarian Epithelial · Slovakia2Completed7
NCT00490659Carcinoma, Non-Small-Cell Lung · Poland2Completed13
NCT00490399Biliary Tract Carcinoma · Korea, Republic of2Completed39
NCT00489996Carcinoma, Non-Small-Cell Lung · China2Completed100
NCT00489983Carcinoma, Non-Small-Cell Lung · Germany, Italy, United Kingdom2Completed91
NCT00383331Carcinoma, Non-Small-Cell Lung · United States2TerminatedJan 200819
NCT00380588Biliary Tract Neoplasms · Japan2CompletedOct 200884
NCT00356525Lung Neoplasms · United States, Brazil, India2TerminatedJun 200841
NCT00334802Breast Neoplasms · Japan2CompletedFeb 200862
NCT00326911Pancreatic Neoplasms · United States2TerminatedOct 200861
NCT00320541Breast Neoplasms · United States, Puerto Rico2CompletedApr 2009187
NCT00316199Breast Neoplasms · China2CompletedApr 200860
NCT00192101Breast Neoplasms · Saudi Arabia2Completed100
NCT00192075Colorectal Neoplasms · United States2Completed84
NCT00192062Breast Neoplasms · Egypt2Completed80
NCT00192049Non-Muscle Invasive Bladder Neoplasms · Israel2Completed90
NCT00192036Carcinoma, Non-Small-Cell Lung · Belgium2CompletedJan 200849
NCT00191971Urologic Neoplasms · Japan2Completed40
NCT00191841Carcinoma, Non-Small-Cell Lung · Russian Federation2Completed50
NCT00191815Breast Neoplasms · Germany, Russian Federation2Completed70
NCT00191789Breast Neoplasms · India2CompletedApr 200965
NCT00191763Carcinoma · Turkey2Completed52
NCT00191711Non-Muscle Invasive Bladder Neoplasms · Italy2Completed43
NCT00191672Breast Neoplasms · United States2Completed120
NCT00191646Genital Neoplasms, Female · United States, Puerto Rico3CompletedAug 2009919
NCT00191620Carcinoma, Non-Small-Cell Lung · Argentina, Brazil, Chile and more2Completed64
NCT00191568Pancreatic Neoplasms · France2Completed45
NCT00191503Adenocarcinoma · Canada2Completed30
NCT00191490Carcinoma, Non-Small-Cell Lung · Italy2Completed162
NCT00191477Urinary Bladder Neoplasms · Germany3TerminatedMar 2008355
NCT00191451Breast Neoplasms · United States2CompletedOct 2008150
NCT00191438Breast Neoplasms · France, Germany, Italy and more3Completed300
NCT00191373Breast Neoplasms · United States2Completed66
NCT00191347Breast Neoplasms · Canada2Completed30
NCT00191334Ovarian Neoplasms · Russian Federation2CompletedDec 200750
NCT00191269Breast Neoplasms · Japan2CompletedMar 200868
NCT00191256Carcinoma, Non-Small-Cell Lung · United States2Completed77
NCT00191243Breast Neoplasms · Finland2CompletedAug 2007237
NCT00191230Carcinoma, Non-Small-Cell Lung · United States2Completed70
NCT00191152Breast Neoplasms · United States, Argentina, Australia and more3CompletedNov 2008475
NCT00191139Carcinoma, Non-Small-Cell Lung · United States, Argentina, China and more2CompletedNov 200864
NCT00191126Carcinoma, Non-Small-Cell Lung · Belgium, Bosnia and Herzegovina, Bulgaria and more3CompletedSep 2007263
NCT00191100Uterine Cervical Neoplasms · Argentina, Bosnia and Herzegovina, India and more3CompletedApr 2008515
NCT00190710Carcinoma, Non-Small-Cell Lung · United States3Completed242
NCT00112346Carcinoma, Non-Small-Cell Lung · United States, Canada2CompletedDec 2006120
NCT00101842Carcinoma, Transitional Cell · United States2Completed61
NCT00071136Lung Neoplasms · United States2Completed48
NCT00069875Carcinoma, Non-Small-Cell Lung · United States, Canada, Germany and more2Completed195
NCT00063570Breast Neoplasms · United States, Puerto Rico2CompletedJan 200873
NCT00061477Mesothelioma · United States2Completed48
NCT00061464Carcinoma, Non-Small-Cell Lung · United States2Completed48

How it is read

Names in the registry

  • “Gemcitabine”, 113 entries
  • “gemcitabine”, 52 entries
  • “gemcitabine hydrochloride”, 17 entries
  • “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
  • “EndoTAG-1 and Gemcitabine”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.